Monitor for any future conversion to a 13D filing, which would signal activist intent. The recent 8-K earnings filing (Nov 9) provides context for evaluating the investment thesis.
ABEO drugs
ABEO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 12 $2.29entry
- T+1 · 4d ago +5.68%α +6.04% · $2.42
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Daniel Kaufman filed an amended Schedule 13G disclosing a 7.3% passive stake in Abeona Therapeutics as of September 30, 2026. The filing is an amendment to a prior 13G, indicating Kaufman's stake increased from a previously undisclosed level. The passive nature and lack of activist intent make this a routine update.
Key Financial Metrics
Key Facts
- Daniel Kaufman reported beneficial ownership of 4,159,099 shares of Abeona Therapeutics common stock as of September 30, 2026.
- The stake represents 7.3% of shares outstanding.
- The filing is an amendment to a prior Schedule 13G, indicating a change in position.
- Kaufman certifies the shares were not acquired with the purpose of changing or influencing control of the issuer.
- The filing is made under Rule 13d-1(c), confirming passive investor status.
Financial Impact
Stake valued at approximately $10.2 million based on $140M market cap and 7.3% ownership.
Risk Factors
- Passive stake filing; no indication of activist intent or imminent changes.
- No financial data or guidance provided in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001099910-26-000305 |
| Document: 0001099910-26-000305-index.html | 0001099910-26-000305 |
| Document: 0001099910-26-000305.txt | 0001099910-26-000305 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $2.59 Now $2.60 +0.39% settles Nov 18
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Viewing Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers